New XEOMIN(R) Is Now Available For The Treatment Of Blepharospasm, Cervical Dystonia And Post-Stroke Spasticity

Main Category: Neurology / Neuroscience
Also Included In: Stroke;  Pain / Anesthetics
Article Date: 23 Jul 2009 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

4 (2 votes)

Healthcare Prof:4 stars

4 (1 votes)


Merz Pharma Canada Ltd. announces new XEOMIN® (Botulinum neurotoxin type A) is now available for prescribing to patients with the following serious, debilitating neuromuscular conditions:

Blepharospasm: The involuntary forced closure of the eyelids. Blepharospasm symptoms may begin with uncontrollable blinking of only one eye, but often both eyes are eventually affected. The spasms may leave the eyelids completely closed causing functional blindness even though the eyes and vision are normal.

Cervical Dystonia(i): Cervical dystonia, also called spasmodic torticollis, is a painful condition in which neck muscles contract involuntarily, causing the head to twist to one side or uncontrollably tilt forward or back.

Cervical dystonia most often occurs in middle-aged women. Symptoms generally begin gradually but after a period of three to five years the condition will often stabilize and not progress beyond that point.

Post-Stroke Spasticity: One of the most physically debilitating effects of a stroke is uncontrolled muscle tightness, often accompanied by pain and reduced function. Patients frequently have difficulty walking or using their hands.

There is a distinction between focal and generalized spasticity. Focal spasticity affects a smaller part of the body, such as a hand or an extremity. Generalized spasticity affects greater areas of the body or the whole body. Because of these differences in severity, the approach to treatment will vary.

For further information on any of these conditions contact your physician.

New XEOMIN®, free from complexing proteins, is now available in Canada. Merz Pharma Canada Ltd. is confident that physicians will find new XEOMIN® to be a neurotoxin option worth considering for many of their patients.

(i) Predominantly rotational form (spasmodic torticollis)

Source
Merz Pharma Canada Ltd

View drug information on Xeomin.


Article adapted by Medical News Today from original press release.
Visit our neurology / neuroscience section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Merz Pharma Canada Ltd. "New XEOMIN(R) Is Now Available For The Treatment Of Blepharospasm, Cervical Dystonia And Post-Stroke Spasticity." Medical News Today. MediLexicon, Intl., 23 Jul. 2009. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/158479.php>

APA
Merz Pharma Canada Ltd. (2009, July 23). "New XEOMIN(R) Is Now Available For The Treatment Of Blepharospasm, Cervical Dystonia And Post-Stroke Spasticity." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/158479.php.

Please note: If no author information is provided, the source is cited instead.


Neurology / Neuroscience

Most Popular Articles



Follow Our Neurology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Neurology / Neuroscience Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »